Other

Boehringer Ingelheim Vetmedica Gmbh

Luis Alejandro Hernandez

Eric Martin Vaughn

Arun V Iyer

Abby Rae Patterson

Christine Margaret Muehlenthaler

Gregory Brian Haiwick

Joseph Gilbert Victoria

Joseph Ralph Hermann

Michael B Roof

Dianna M Murphy Jordan

Bailey Arruda

Troy James Kaiser

Luis Gabriel Gimenez-Lirola

Dave Michael Anstrom

Pablo E Pineyro Pineiro

Jorge E Gonzalez

Scott Jeffrey Ackerman

Lea Ann Hobbs

Sean O'conner

Abby Rea Patterson

Jennifer L English

Gregory Haiwick

Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.

PCV2 ORF2 protein variant and virus like particles composed thereof

The present invention relates to a vaccine for protecting a pig against diseases associated with corona virus infection including porcine epidemic diarrhea virus (PEDV) and/or porcine deltacorona virus (PDCoV). The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen, and/or an adjuvant inactivated/killed PDCoV (e.g., chemically inactivated PDCoV virus), and/or recombinant PDCoV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and/or PDCoV and methods of producing the porcine epidemic diarrhea virus and/or porcine deltacorona virus vaccine are also provided.

Porcine coronavirus vaccines

The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 3 (PCV3) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV3 infection.

Porcine Circovirus Type 3 (PCV3) vaccines, and production and uses thereof

The present invention relates to the use of an immunogenic composition that comprises a porcinetype 3 (PCV3) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV3 infection.

The present invention relates to killed/inactivated and/or recombinant Senecavirus A immunogenic compositions and vaccines, and methods of preventing or treating animals in need of with such an immunogenic compositions and vaccines.

Senecavirus a immunogenic compositions and methods thereof

The present invention relates to immunogenic compositions, wherein the immunogenic compositions include a recombinant spike antigen porcine epidemic diarrhea virus (PEDV). The immunogenic compositions commonly include an oil-in-water emulsion as an adjuvant. Methods for producing the immunogenic compositions and the recombinant PEDV spike antigen are also provided.

Porcine epidemic diarrhea virus vaccine

The present invention relates to an immunogen-carrier, wherein the immunogen-carrier is preferably a virus-like particle (VLP) composed of a plurality of a modified PCV2 ORF2 protein. In particular, the present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a compliance marker for vaccines including a subunit antigen, and a DIVA (Differentiating Infected from Vaccinated Animals) system which makes it possible to differentiate between animals infected with a pathogen and animals treated with a subunit antigen derived from said pathogen.

PCV2 ORF2 carrier platform

Vaccination methods to control PCVinfection with different PCVsubtypes are disclosed. Specifically, a PCVsubtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCVof the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCVof the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCVof the same PCV2b and/or a different subtype. The present invention in particular relates to PCVsubtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCVORFprotein that does not contain such mutation.

The present invention relates to a vaccine for protecting a pig against diseases associated with porcine epidemic diarrhea virus. The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and methods of producing the porcine epidemic diarrhea virus vaccine are also provided.

A machine for manufacturing croquettes from a source of elastic food mass continuously discharged from a nozzle assembly having a reciprocating chopper controlled by sensors for severing the mass into croquettes, a plurality of conveyors for moving said croquettes through tunnel assemblies for compressing said croquettes into a desired shape and a shaker assembly for breading said croquettes and providing a frictional means for rolling said croquettes through said tunnels.

Growing community of inventors

Story City, IA, United States of America

Luis Alejandro Hernandez